Retatrutide

Definition

Retatrutide is the Eli Lilly metabolic drug candidate described in the episode as a triple agonist targeting GLP-1, GIP, and glucagon receptors.

Current Synthesis

The episode frames retatrutide as the next premium frontier in the GLP-1 and peptide boom. David Friedberg describes phase-three data with large weight-loss and cardiometabolic marker improvements, while emphasizing that he is not a doctor and that approval timing depends on review. The distinctive source claim is that glucagon activation may increase metabolism and fat-energy use, possibly improving body-composition outcomes compared with earlier incretin drugs.

Retatrutide should not be treated as a routine consumer peptide protocol. In this source it is still pending approval, clinically bounded, and discussed through trial averages rather than individualized medical guidance. Its wiki importance is that it links regulated peptide-drug development with gray-market peptide excitement and fitness-oriented body-composition narratives.

Key Claims

• Retatrutide is described as a GLP-1/GIP/glucagon triple agonist, making it mechanistically distinct from single- or dual-target incretin drugs.
• The source reports phase-three improvements in weight, lipids, liver fat, and A1C, but those figures remain source-scoped trial claims.
• The glucagon component is framed as a possible fat-burning and muscle-preservation advantage.
• Approval timing is projected around mid-2027 in the episode but remains dependent on FDA review.
• Fitness and “de-aging” interest should be separated from approved indication, clinician oversight, and long-term safety evidence.

Evidence

• Mechanism: OpenAI Misses Targets, Codex vs Claude, Elon vs Sam Trial, Big Hyperscaler Beats, Peptide Craze describes retatrutide as binding GLP-1, GIP, and glucagon receptors.
• Trial-result claims: OpenAI Misses Targets, Codex vs Claude, Elon vs Sam Trial, Big Hyperscaler Beats, Peptide Craze reports large average weight loss and improvements in non-HDL cholesterol, triglycerides, liver fat, and A1C.
• Use and timing boundary: OpenAI Misses Targets, Codex vs Claude, Elon vs Sam Trial, Big Hyperscaler Beats, Peptide Craze says approval could come around mid-2027 and discusses fitness/body-composition interest as speculative.

Counterevidence & Qualifications

The page records a podcast summary of clinical claims, not the trial protocol or prescribing label. Retatrutide was discussed as pending approval in the source; therefore dosing, contraindications, durability, adverse events, muscle preservation, liver/cardiac effects, and off-label fitness use remain medical questions requiring formal evidence and clinician supervision.

What Changed

• Created retatrutide as a regulated next-generation incretin-drug candidate connected to GLP-1 competition and peptide culture.

Related Concepts

• GLP-1 Agonists - mature incretin-drug category retatrutide extends.
• GLP-1 Body Composition Stack - fitness/body-composition branch that may borrow attention from retatrutide.
• Peptide Evidence Hierarchy - framework for separating regulated peptide drugs from weaker evidence zones.
• Medical Risk Management - clinical supervision and monitoring boundary.
• Lifestyle Weight Management / 生活方式体重管理 - maintenance and behavior context around weight-loss interventions.